Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) initially responds well to EGFR tyrosine kinase inhibitors (TKIs).
• Resistance and recurrence are common after TKI treatment, limiting therapeutic options.
• Immune checkpoint inhibitors (ICIs) offer a new approach for advanced NSCLC, but their efficacy in EGFR-mutant subgroups needs further investigation.

Purpose of the Study:

• To explore various immune checkpoint blockade strategies in EGFR-mutant NSCLC.
• To evaluate the combination of ICIs with TKIs, chemotherapy, radiation, and antiangiogenic agents.
• To understand the molecular and immune characteristics of EGFR mutations and their impact on ICI therapy outcomes.

Main Methods:

• Review of current literature on immune checkpoint blockade strategies in EGFR-mutant NSCLC.
• Analysis of combination therapies involving ICIs with TKIs, chemotherapy, radiation, and antiangiogenic agents.
• Summarization of evidence on molecular features, immune signatures, and ICI therapy outcomes in EGFR-mutant NSCLC.

Main Results:

• Monotherapy with ICIs has not shown superiority in long-term survival for EGFR-mutant NSCLC in second-line treatment.
• Combination strategies of ICIs with other therapies are being investigated for both first-line and subsequent treatments.
• Heterogeneous molecular features and immune signatures in EGFR mutations may influence response to ICI therapy.

Conclusions:

• Optimal application of ICIs in EGFR-mutant NSCLC requires further research, particularly in combination therapies.
• Understanding the interplay between EGFR mutations and the tumor immune microenvironment is crucial for improving ICI efficacy.
• Developing tailored immune-based treatment strategies is essential for patients with EGFR-mutant NSCLC who have exhausted targeted therapies.